Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Journal Article
PMID (32558295)
Authors Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong HS, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M
Title Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.
Journal EMBO molecular medicine
Vol 12
Issue 7
Date 2020 Jul 07
URL
Abstract Text A subset of lung adenocarcinomas is driven by the EML4-ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on-target mutations or parallel pathway alterations is a major clinical challenge. Exploring these mechanisms of resistance, we found that EML4-ALK cells parental or resistant to crizotinib, ceritinib or alectinib are remarkably sensitive to inhibition of CDK7/12 with THZ1 and CDK9 with alvocidib or dinaciclib. These compounds robustly induce apoptosis through transcriptional inhibition and downregulation of anti-apoptotic genes. Importantly, alvocidib reduced tumour progression in xenograft mouse models. In summary, our study takes advantage of the transcriptional addiction hypothesis to propose a new treatment strategy for a subset of patients with acquired resistance to first-, second- and third-generation ALK inhibitors.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
EML4 - ALK lung adenocarcinoma sensitive Alvocidib Preclinical - Cell line xenograft Actionable In a preclinical study, Alvocidib (flavopiridol) treatment induced cell cycle arrest and apoptosis, reduced viability, and inhibited proliferation of EML4-ALK harboring parental lung adenocarcinoma, and Xalkori (crizotinib), Zykadia (ceritinib), and Alecensa (alectinib)-resistant cells in culture, and reduced tumor growth in Xalkori (crizotinib) and Alecensa (alectinib)-resistant cell line xenograft models (PMID: 32558295). 32558295
EML4 - ALK lung adenocarcinoma sensitive Dinaciclib Preclinical - Cell culture Actionable In a preclinical study, Dinaciclib (SCH 727965) treatment induced apoptosis, reduced viability, and inhibited proliferation of EML4-ALK harboring parental lung adenocarcinoma, and Xalkori (crizotinib), Zykadia (ceritinib), and Alecensa (alectinib)-resistant cells in culture (PMID: 32558295). 32558295
EML4 - ALK lung adenocarcinoma predicted - sensitive Alvocidib + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Alvocidib (flavopiridol) treatment in combination with Xalkori (crizotinib) reduced viability of Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK in culture but did not demonstrate synergistic effects compared to Alvocidib (flavopiridol) treatment alone (PMID: 32558295). 32558295
EML4 - ALK lung adenocarcinoma sensitive THZ1 Preclinical - Cell culture Actionable In a preclinical study, THZ1 treatment reduced viability and inhibited proliferation of EML4-ALK harboring parental lung adenocarcinoma, and Xalkori (crizotinib), Zykadia (ceritinib), and Alecensa (alectinib)-resistant cells in culture (PMID: 32558295). 32558295
EML4 - ALK lung adenocarcinoma predicted - sensitive Lorlatinib Preclinical - Cell line xenograft Actionable In a preclinical study, EML4-ALK harboring Xalkori (crizotinib) and Zykadia (ceritinib)-resistant lung adenocarcinoma cell lines demonstrated resistance to Lorbrena (lorlatinib) treatment in culture, however, reduced viability of Alecensa (alectinib)-resistant cells, and inhibited tumor growth in a cell line xenograft model with Xalkori (crizotinib) resistance (PMID: 32558295). 32558295